Clémence Kopff
Investment Manager
In Portfolio
Nexpring Health
Nexpring Health is a global leader in Assisted Reproductive Technology (ART), providing consumables and equipment for in-vitro fertilization (IVF) procedures to hospitals, specialized clinics, and IVF laboratories across more than 115 countries.
Overview
Nexpring Health was established in 2024 via two primary transactions: the carve-out of Cook Medical's Reproductive Health portfolio and the take-private of Hamilton Thorne Ltd. In January 2025, Nexpring Health signed the acquisition of Irvine Scientific's Reproductive Health assets, expanding its portfolio to vitrification and embryo culture media. The combined group offers a comprehensive range of high-quality and innovative ART products that improve the outcomes and accessibility of fertility treatments globally.
Head Office
Nexpring Health is headquartered in the USA.
Global Sales
Nexpring Health serves over 3,000 fertility clinics and IVF laboratories across more than 115 countries worldwide.
Healthcare sector2024 Entry into PortfolioFund Astorg VIII650 EMPLOYEESHealthcare sector2024 Entry into PortfolioFund Astorg VIII650 EMPLOYEESHealthcare sector2024 Entry into PortfolioFund Astorg VIII650 EMPLOYEESHealthcare sector2024 Entry into PortfolioFund Astorg VIII650 EMPLOYEES
Meet the team behind our deep
expertise and market-leading results
Olivier Lieven
Partner, Healthcare Flagship
Tobias Nordblom
Managing Director, Healthcare Flagship
